candesartan

Phase 2UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hypertrophic Cardiomyopathy

Conditions

Hypertrophic Cardiomyopathy

Trial Timeline

— → —

NCT ID

NCT00430833

About candesartan

candesartan is a phase 2 stage product being developed by AstraZeneca for Hypertrophic Cardiomyopathy. The current trial status is unknown. This product is registered under clinical trial identifier NCT00430833. Target conditions include Hypertrophic Cardiomyopathy.

What happened to similar drugs?

3 of 13 similar drugs in Hypertrophic Cardiomyopathy were approved

Approved (3) Terminated (0) Active (10)

✅RanolazineGilead SciencesApproved

✅MavacamtenBristol Myers SquibbApproved

🔄Mavacamten + PlaceboLianBioPhase 3

🔄Mavacamten + PlaceboBristol Myers SquibbPhase 3

🔄MavacamtenBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00430833	Phase 2	UNKNOWN	—	—	Hypertrophic Cardiomyopathy
NCT00679640	Pre-clinical	Completed	Jan 1, 2008	Jul 1, 2010	Heart Failure
NCT00320970	Pre-clinical	Completed	Aug 1, 2002	Sep 1, 2004	Diabetic Nephropathy
NCT00252694	Phase 3	Completed	Aug 1, 2001	Apr 1, 2008	Type 2 Diabetes
NCT00252720	Phase 3	Completed	Aug 1, 2001	Apr 1, 2008	Type 1 Diabetes
NCT00130975	Phase 3	Completed	Apr 1, 2001	Sep 1, 2005	Atrial Fibrillation
NCT00150631	Phase 3	UNKNOWN	Nov 1, 2000	Dec 1, 2014	Hypertension

Competing Products

20 competing products in Hypertrophic Cardiomyopathy

See all competitors

Product	Company	Stage	Hype Score
Mavacamten	LianBio	Phase 1	19
Mavacamten + Placebo	LianBio	Phase 3	30
CT-G20 + Placebo	Celltrion	Phase 1	21
LCZ696 + Placebo	Novartis	Phase 2	35
Eleclazine + Placebo	Gilead Sciences	Phase 2/3	30
Ranolazine	Gilead Sciences	Approved	43
PF-06473871 + PF-06473871	Pfizer	Phase 2	27
PF-06473871 + PF-06473871	Pfizer	Phase 2	35
EXC 001 + EXC 001 + EXC 001 + EXC 001	Pfizer	Phase 2	35
Mavacamten	Bristol Myers Squibb	Approved	50
Mavacamten + Placebo	Bristol Myers Squibb	Phase 3	44
Mavacamten	Bristol Myers Squibb	Pre-clinical	30
Mavacamten	Bristol Myers Squibb	Pre-clinical	33
Mavacamten	Bristol Myers Squibb	Approved	47
MYK-224	Bristol Myers Squibb	Phase 2	27
mavacamten	Bristol Myers Squibb	Phase 2/3	38
mavacamten	Bristol Myers Squibb	Phase 2	35
Mavacamten	Bristol Myers Squibb	Pre-clinical	33
Mavacamten	Bristol Myers Squibb	Pre-clinical	30
Mavacamten + Placebo	Bristol Myers Squibb	Phase 3	40